BIOMAX INFORMATICS Announces Expansion of Long-Term Business Relationship With DSM To Develop Novel Bioinformatics Solutions for

BIOMAX INFORMATICS Announces Expansion of Long-Term Business Relationship With DSM To Develop Novel Bioinformatics Solutions for Life Sciences R&D

PLANEGG, Germany--(BUSINESS WIRE)--Biomax Informatics today announced the expansion of its long-term licensing and services agreement with Royal DSM to include solutions for synthetic biology using Biomax's BioXMTM Knowledge Management Environment. The BioXM system is a unique generic software platform for dynamic modeling, visualization and analysis of biological and biomedical networks. By enabling an agile process to develop new life science applications through easy configuration and customization, the BioXM system allows new solutions to be deployed quickly to large user communities. Leveraging the capabilities of the BioXM system in synthetic biology allows a purpose-oriented engineering approach.

"By now we have used the new BioXM system in several different areas"
"DSM, as a science-based company in health, nutrition and materials, stands for innovation," Dr. Hans Roubos, Senior Scientist at DSM, said. "We are committed to on-going exploration of new frontiers in science and technology as a basis for sustainable growth. Leveraging best-in-class technology, such as BioXM, is part of that strategy."

Biomax Informatics has been working with DSM since 1998. DSM had early access to the next generation of the BioXM system. Released in March 2011, BioXM version 4 further simplifies the rollout of dedicated solutions by adding a customizable web portal builder that allows quick publishing of BioXM-based applications on the Web.

"By now we have used the new BioXM system in several different areas," said Dr. Marco de Groot, Scientist Bioinformatics at DSM. "The system is outstanding in terms of flexibility and its ability to be tuned to our needs. Its solution-building approach is unprecedented: rolling-out a new application to hundreds of end-users takes only weeks. Most importantly, we are able to continuously adapt the system while staying in production, which greatly reduces cost."

"We are excited to see the use of our BioXM platform expanding to the field of synthetic biology," Dr. Klaus Heumann, CEO of Biomax Informatics, added. "The ability to combine scientific excellence and ease of use in a unified, sustainable platform with a highly agile solution-building process makes the BioXM Knowledge Management Environment unique - and makes all the difference for our customers."

 

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.